Varian Medical : Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Jernigan Capital, Inc., Momenta Pharmaceuticals, Inc., NTN Buzztime, Inc., Principia Biopharma Inc., Spring Bank Pharmaceuticals, Inc., Varian Medical Systems, Inc., and Yintech Investment Holdings Limited

August 26, 2020 at 06:40 pm EDT

NEW YORK, Aug. 26, 2020 /PRNewswire/ --

Cancer Genetics, Inc. (NASDAQ: CGIX)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of CGIX with StemoniX, Inc.

If you are a JCAP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Jernigan Capital, Inc. (NYSE: JCAP, JCAP-PB)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of JCAP to an affiliate of NexPoint Advisors, L.P. for $17.30 per share.

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of MNTA to JNJ for $52.50 per share in cash.

If you are a MNTA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

NTN Buzztime, Inc. (NYSE: NTN)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of NTN with Brooklyn ImmunoTherapeutics LLC.

If you are a NTN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Principia Biopharma Inc. (NASDAQ: PRNB)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of PRNB to Sanofi for $100 per share.

If you are a PRNB investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of SBPH to F-star Therapeutics, Limited.

If you are a SPBH investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Varian Medical Systems, Inc. (NYSE: VAR)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of VAR to Siemens Healthineers AG.

If you are a VAR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Yintech Investment Holdings Limited (NASDAQ: YIN)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of YIN to members of YIN management.

If you are a YIN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING.© 2020 Lifshitz Law Firm, P.C. The law firm responsible for this advertisement is Lifshitz Law Firm, P.C., 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law Firm, P.C.
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com

View original content:http://www.prnewswire.com/news-releases/lifshitz-law-firm-pc-announces-investigation-of-cancer-genetics-inc-jernigan-capital-inc-momenta-pharmaceuticals-inc-ntn-buzztime-inc-principia-biopharma-inc-spring-bank-pharmaceuticals-inc-varian-medical-syste-301119276.html

SOURCE Lifshitz & Miller Law Firm

Varian and Nova Scotia Health Form First Multi-Disciplinary Oncology Partnership to Catalyze Advancements in Cancer Care	Jan. 04	CI
Varian Medical Systems, Inc. acquired Aspekt Solutions.	23-09-25	CI
Varian Announces First Participant Treated in RADIATE-VT Clinical Trial of Cardiac Radioablation for Patients with Refractory Ventricular Tachycardia	23-05-19	CI
Varian Collaborating with Nova Scotia Health to Transform Cancer Care	23-02-17	CI
Varian Receives Investigational Device Exemption for Flash Technology Clinical Trial, FAST-02	22-06-27	CI
Adaptiiv Collaborates with HP and Varian to Enhance Personalization in Radiation Oncology with 3D Printed Medical Devices	22-05-06	CI
Oulu University Hospital in Finland Enters Long-Term Strategic Partnership with Varian and Siemens Healthineers	22-01-19	CI
Varian and Icon Oncology Partner to Establish Value-Based Cancer Treatment Hub for Southern Africa	21-12-14	CI
Varian and the Cincinnati Children's/UC Health Proton Therapy Center Complete Enrollment of FAST-01, First Human Clinical Trial of FLASH Therapy for Cancer	21-10-25	CI
Varian Medical Systems, Inc. Receives FDA "Breakthrough Device Designation" For Embozene® Microspheres For Genicular Artery Embolization For Symptomatic Knee Osteoarthritis	21-10-13	CI
Elekta : Medical equipment maker Elekta sees higher supply chain costs, shares fall	21-08-25	RE
Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian	21-08-05	CI
Siemens : Targets Higher Full-Year Profit As Demand Surge Beats Supply Chain Woes	21-08-05	MT
Siemens Backs Fiscal Year 2021 Outlook, Including Varian Deal	21-06-24	DJ
Varian Receives FDA "Breakthrough Device Designation" for its Cardiac Radioablation System for Treatment of Refractory Ventricular Tachycardia (VT)	21-05-26	CI
Siemens : Raises FY21 Outlook As Fiscal H1 Profit Doubles	21-05-07	MT
Siemens Healthineers : Strong COVID-19 Antigen Test Sales Prompt Siemens Healthineers Full-Year Guidance Boost	21-05-03	MT
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 EQUAL WEIGHTED	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P TMI Index	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P Global BMI Index	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 Growth	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P Global 1200	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 Health Care Equipment & Services (Industry Group)	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 Health Care	21-04-20	CI

Varian Medical Systems, Inc.

Equities

VAR

US92220P1057

Varian Medical : Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Jernigan Capital, Inc., Momenta Pharmaceuticals, Inc., NTN Buzztime, Inc., Principia Biopharma Inc., Spring Bank Pharmaceuticals, Inc., Varian Medical Systems, Inc., and Yintech Investment Holdings Limited

Latest news about Varian Medical Systems, Inc.

Chart Varian Medical Systems, Inc.

Company Profile